OOIR: Observatory of International Research

Papers

(The TQCC of Best Practice & Research Clinical Endocrinology & Metabolism is 15. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
The novel concept of “Onco-Immuno-Endocrinology” led to the discovery of new clinical entity “paraneoplastic autoimmune hypophysitis”	111
Editorial Board	111
Editorial Board	73
Editorial Board	72
Recent progress in molecular classification of phaeochromocytoma and paraganglioma	60
Genetics of pubertal timing	54
Gonadectomy in individuals with a difference of sex development – For whom, when, why, and why not?	54
Treatment of acromegaly with the nonpeptide, highly selective somatostatin receptor type 2 agonist paltusotine	52
Growth hormone replacement in adults with cured acromegaly: Efficacy and safety	50
Menopausal hormone therapy for the management of osteoporosis	47
Coronavirus disease 2019 and vitamin D	43
Regulation of bone mass: A splendid Orchestra	43
Polygenic risk scores for dyslipidemia and atherosclerotic cardiovascular disease: Progress toward clinical implementation	42
Editorial Board	40
The role of androgens in transgender medicine	38
Rare forms of genetic steroidogenic defects affecting the gonads and adrenals	38
Sexual health and contraception in the menopause journey	38
Prenatal exposure to phthalate esters and its impact on child development	37
Immune checkpoint inhibitor-related thyroid dysfunction	37
Editorial Board	36
Haematological actions of androgens	33
Cardiometabolic outcomes of early onset hypogonadism in males	32
Optimal surgical approach for digestive neuroendocrine neoplasia primaries: Oncological benefits versus short and long-term complications	32
Remnant lipoprotein particles and cardiovascular disease risk	31
Molecular basis of symptomatic sporadic primary hyperparathyroidism: New frontiers in pathogenesis	30

Acquired disorders of phosphaturia: Beyond tumor-induced osteomalacia	29
Non-oestrogen-based and complementary therapies for menopause	27
The effect of osteoporosis treatment on bone mass	26
Safety of long-term use of daily and long-acting growth hormone in growth hormone-deficient adults on cancer risk	26
Medullary thyroid cancer - An update	26
Type 1 diabetes related to immune checkpoint inhibitors	25
Epidemiology and risk factors for hypopituitarism due to traumatic brain injury	25
Editorial Board	25
Pathogenic role of Th17 cells in autoimmune thyroid disease and their underlying mechanisms	24
Metabolic complications and their mechanisms in patients with craniopharyngioma	24
Radioiodine therapy in the different stages of differentiated thyroid cancer	24
Endocrine-disrupting chemicals and behaviour: A high risk to take?	24
Immune checkpoint inhibitor-related hypophysitis	23
Onco-immuno-endocrinology: An emerging concept that links tumor, autoimmunity, and endocrine disease	23
Hormone therapy for menopause and premature ovarian insufficiency	23
Approach to patients with elevated low-density lipoprotein cholesterol levels	22
Editorial Board	22
Pathophysiology of thyroid-associated orbitopathy	22
Safety of androgen therapy in men with prostate cancer	22
The role of hormone therapy in urogenital health after menopause	21
Personalized management for phaeochromocytomas and paragangliomas in Latin America: A genetic perspective	21
Best practice and research clinical endocrinology and metabolism issue on phaeochromocytomas and paragangliomas	21
Best Practice and Research Clinical Endocrinology and Metabolism focusing on Growth Hormone Deficiency in Adults – New Perspectives	21
Pathophysiology and diagnosis of neuroendocrine abnormalities in patients with traumatic brain injury	20
History of androgens and androgen action	20
Localization in primary hyperparathyroidism	20
Surgical outcomes in patients with acromegaly: Microscopic vs. endoscopic transsphenoidal surgery	20
Editorial Board	19
Editorial Board	19
Genotype-phenotype correlations in Graves’ disease	18
Recent advances in algorithms predicting hemodynamic instability undergoing surgery for phaeochromocytoma and paraganglioma	18
Endocrine disrupting chemicals and bone	18
Post cancer care in women with an increased risk of malignancy or previous malignancy: The use of hormone replacement therapy and alternative treatments	18
Genetics of anti-Müllerian hormone and its signaling pathway	18
Preface	17
Best practice & research clinical endocrinology & metabolism focusing on the menopause – Diagnostic and therapeutic strategies	17
Hormone replacement in disorders of sex development, and long-term effects	17
“Micromegaly”: Acromegaly with apparently normal GH, an entity on its own?	17
Exercise and physical activity in individuals at risk of fracture	16
Care quality improvement in differences of sex development	16
COVID-induced thyroid autoimmunity	15
Anaplastic thyroid cancer: An update	15
Chemokines in thyroid autoimmunity	15
The options for delayed surgery – Is there evidence available for delayed genitoplasty in differences/disorders of sex development?	15
Editorial Board	15